The technology centers on a B7-H3-specific monoclonal antibody, mAb 376.96, designed to target an epitope predominantly expressed on malignant cells. Detailed studies have validated its unique binding characteristics through both in vitro and in vivo experiments, confirming its high specificity and potential utility in cancer research, diagnostics, and therapeutics. Its development, built on extensive university research, reflects a sophisticated process that ensures the antibody’s precise affinity for the intended B7-H3 antigen, offering promise for more targeted interventions.
Description
This technology distinguishes itself by its rigorous characterization and validated in vivo efficacy, setting it apart from earlier, less-defined antibodies. The clear delineation of its epitope-specific binding enables enhanced targeting of malignant cells while potentially reducing collateral effects on healthy tissues. Commercial interest, as indicated by industry players like ImmunGene, further underlines its innovative edge in the competitive field of cancer treatment development, positioning it as a promising candidate for advancing precision medicine initiatives in oncology.
Applications
- Cancer targeted therapy
- Tumor diagnostic imaging
- Cancer biomarker detection
- Immuno-oncology research tool
Advantages
- Enhanced targeting: Specifically binds malignant cells while sparing healthy tissue.
- Diagnostic and therapeutic potential: Offers advancements in cancer detection and treatment.
- In vivo validation: Demonstrated efficacy in animal studies supports real-world applications.
- Improved specificity: Provides a more accurately-characterized antibody compared to earlier versions.
IP Status
Research Tool
